Feed SHEZF
SH

Shenzhen Hepalink Pharmaceutical Group Co., Ltd. SHEZF OTC · Healthcare · China

$0.47 +0.00% +$0.00

Summary

40 / 100 · Bulios Score

What speaks for it

  • Out of every 100 CNY of revenue, 33 CNY is left as free cash.
  • The price moves less than the market (beta 0.31).

What to watch

  • Revenue fell by 8.5% a year over the last 3 years.
  • It pays out more in dividends than it earns: 109% of profit.
  • It earns only 1.0 CNY a year on every 100 CNY of invested capital.
  • Out of every 100 CNY of revenue, only 3.7 CNY is left as net profit.

Bulios Scoring describes a company's quality and track record, not its future return. A high score is not a buy signal. Learn more

Score in detail

Price

Is it expensive?

Fairly priced
Bulios Fair Price
Fair Value Price today $0.47

By our assumptions the price matches the value of the business: the two differ by less than 10 %.

P/E today 24.2 7.9% higher
5-year average P/E 22.4
P/E today 24.2
Drug Manufacturers - Specialty & Generic industry median

Bulios Fair Price is an estimate of a stock's fair value from the Bulios valuation model. It is an input for your own analysis, not investment advice. How does it work?

Today you pay 24.2 CNY for 1 CNY of yearly profit. Over the last five years it was 22.4 CNY on average.

Valuation in detail

Is it growing?

It is shrinking

Revenue (CNY)

Diluted EPS (CNY)

  • Analyst estimate

Revenue grew by 0.5% a year over 5 years. Over the last 3 years it fell by 8.5% a year. Earnings per share fell by 22% a year over the last 3 years.

Growth in detail

Does it make money?

Reasonably

Where 100 CNY of revenue goes

Net profit, industry median (Drug Manufacturers - Specialty & Generic) 9.9 CNY

Out of every 100 CNY of revenue, 3.7 CNY is left as net profit.

Profitability in detail

Is it financially healthy?

Yes

Repaying all its debt would take 1.7 years of free cash flow. It holds more cash than debt.

Financial health in detail

Does it pay a dividend?

High, at risk
Yield
4.51%
Paid out of profit
109%

You receive $0.02 per share a year. The payout is more than the company can comfortably cover.

Dividends in detail

What do analysts expect?

No coverage

No analyst covers this stock.

Analysts in detail

What does it earn on?

By product

The company reports no revenue by product.

By region

The company reports no revenue by region.

Segments in detail

We use essential cookies to run the website and optional analytics cookies to measure usage.

Privacy policy